Sidoti downgraded Surmodics to Neutral from Buy with a $43 price target after the company entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRDX: